In February and March of 2007, the U.S. Food and Drug Administration (FDA) issued an alert to provide new safety information for erythropoiesis-stimulating agents (ESAs) under the brand names Aranesp® (darbepoetin alfa), Epogen® (epoetin alfa), and Procrit® (epoetin alfa). Analyses of four new studies in patients with cancer, using ESAs, found a higher chance of serious and life-threatening side effects and/or death with the use of ESAs. To read the full FDA safety warning, click here.
While similar in treating anemia, Anadrol®-50 (oxymetholone) is different than the brands Aranesp®, Epogen®, and Procrit®. Anadrol-50 belongs to a class of drugs called anabolic steroids, which are similar to the male hormone testosterone. Anadrol-50 is the only oral anabolic steroid that has been approved by the U.S. Food and Drug Administration for the treatment of anemias caused by deficient red blood cell production. Unlike some other anabolic steroids, which must be injected often, Anadrol-50 is a tablet that is taken by mouth. Also, Anadrol-50 does not replace other supportive measures, but works together with other treatments that your doctor may give you for anemia. SEE FULL BOXED WARNING FOR MORE INFORMATION ON THESE CONDITIONS IN THE FULL PRESCRIBING INFORMATION.
Speak to your doctor about anemia, Anadrol-50, and recent FDA safety warnings: